Navigation Links
Data Show FluMist May Reduce Seasonal Influenza Burden Among,,,Children in School, Daycare Settings

hes, decreased appetite, abdominal pain, and decreased activity/feeling of tiredness/weakness.

Please see the Prescribing Information for the currently available formulation of FluMist at http://www.flumist.com/pdf/prescribinginfo.pdf, visit www.flumist.com, or call 1-877-633-4411 for additional information.

On January 5, 2007, the FDA approved MedImmune's supplemental Biologics Licensing Application (sBLA) for a refrigerated version of FluMist, which will be manufactured for the 2007-2008 influenza season. Prior versions required frozen storage. Due to the seasonal nature of influenza vaccine, full prescribing information for the refrigerated version does not yet contain complete details on vaccine strains to be included for next season's vaccine. However, preliminary prescribing information can be found at http://www.fda.gov/cber/label/inflmed010507LB.pdf.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement contains, in addition to historical information, certain "forward-looking statements" regarding the potential prospects of and the results of clinical trials for FluMist. Such forward-looking
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
11. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Post Your Comments:
(Date:10/6/2008)...nking polyphenol-rich 100% Concord grape,juice was...ntake or body,weight, CONCORD, Mass., Oct. 6 /PRN...-rich Concord grape juice did not cause significan...appetite and was shown to reduce waist,circumferen...ual Meeting of,the American College of Nutrition i...
(Date:10/3/2008)...ase Inhibitors for Cancer Treatments, INDIANAPOLI...stCall/ --,Eli Lilly and Company (NYSE: LLY ) and...ay announced that the two companies have entered,i...ent related to,Deciphera,s preclinical B-Raf kinas...ology therapeutics., The collaboration will apply...
(Date:10/2/2008)...RNewswire/ -- Calabar AB announced today,that thei... mouth"),patients has been initiated. Specifically...s between the ages of 20 to 75. The objective of t...ucceeding Phase III efficacy,study., Xalieve(TM) ...hysostigmine. It is administered locally in the mo...
(Date:10/1/2008)...tial of Amylin,s integrated neurohormonal ... DIEGO, Oct. 1 /- Amylin Ph...ed that new data for its pipeline obesity,candidat... Meeting of The,Obesity Society in Phoenix October...of the largest and most comprehensive scientific c...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 2Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement 3Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Docs Issue Guideline on Screening for Osteoporosis in Men 18604 1Docs Issue Guideline on Screening for Osteoporosis in Men 18604 2iCAD Reports First Quarter 2008 Financial Results 5164 1iCAD Reports First Quarter 2008 Financial Results 5164 2iCAD Reports First Quarter 2008 Financial Results 5164 3iCAD Reports First Quarter 2008 Financial Results 5164 4iCAD Reports First Quarter 2008 Financial Results 5164 5iCAD Reports First Quarter 2008 Financial Results 5164 6iCAD Reports First Quarter 2008 Financial Results 5164 7iCAD Reports First Quarter 2008 Financial Results 5164 8iCAD Reports First Quarter 2008 Financial Results 5164 9Pharm Olam Finds VoIP Solution in Taridium LLC 5160 1Pharm Olam Finds VoIP Solution in Taridium LLC 5160 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 1Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 2Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 3Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 4Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 5Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 6Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 7Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 8Advanced Life Sciences Announces First Quarter 2008 Financial Results 5158 9
...ING, N.J.--(BUSINESS WIRE)--Apr 19, 2007 - Antares...ts from a recently completed,site application stud...TD(TM) transdermal gel, was absorbed on a bioequiv...ee different skin site,locations., The study was a...lication site pharmacokinetic study. The trial enr...
...Unique Viral Kinetics Profile, LAUSANNE, Switzerla...p (Debiopharm), a global independent biopharmaceut...s medical conditions,presented additional results...ilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatit...esented at the 42nd,Annual Meeting of the European...
Other Medicine Technology:Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4
(Date:10/6/2008)... Lutherville-based civil litigation and criminal...on Co. after jury awarded $3.2 million to plaintif...herville, Maryland ((Lexis Nexis) October 6, 2008 ...l.com/ [Miller, Murtha & Psoras] have successf...lf of a Maryland welder who was awarded more than ...
(Date:10/5/2008)...considerable disparities in survival related to ra...ead and neck cancer. Published in the November 15,...f the American Cancer Society, the study indicates...tment could improve outcomes for these cancers amo... studies have examined disparities in cancer survi...
(Date:10/5/2008)...ospitalized kids with painful ailments from broken...killing drugs known as opiates. The medications bl...nstipation, for instance, is one side effect that ...spital stay. , "No parent wants their child in t...Sharek, MD, MPH, medical director for quality mana...
(Date:10/5/2008)...tle exercise goes a long way toward helping severe... and complete important daily tasks, according to ..., In a pre-program assessment where patients repo...per week, individuals who were more active reporte...ed improvements in their ability to perform daily ...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 3Health News:A little exercise goes a long way for severely obese 2
...s from the Harvard School of Public Health now rev...n health risks. They have found that women who car...isk of coronary heart disease. The findings were r... which had collected data on caregiving and corona...
...ming in laboratory studies that one of the substan...hives--may inhibit the development of tooth decay...., found that propolis// considerably reduces denta...r of glucosyltransferase (Gtf) enzymes, enzymes th...
...fferent specialties, recently joined hands to demo...er patients. Dr. Peter Costantino, an otolaryngolo...n fatal tumor in Angela Carrozza’s nasal cavity an...iety of Clinical Oncology, nearly 38,000 cases of ...
...illion people go to the Emergency Room(ER) with ch... Most receive an ECG and other standard tests to d...r serious heart problems. However, ECGs can be com... place. ECGs are also sometimes unable to identify...
Other Medicine News:
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: